Assessment the Correlations of Hormones, Lipid Profiles, Oxidative Stress, and Zinc Concentration in Iraqi Women with Polycystic Ovary Syndrome

Overview

Journal Rep Biochem Mol Biol

Specialty Biochemistry

Date 2021 Mar 2

PMID 33649720

Citations 4

Authors

Ashwaq Shenta

Khansaa Saud

Ali Al-Shawi

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a hormonal disorder in women with unknown causes and is the leading cause of infertility in women of reproductive age, presenting a wide range of clinical manifestations worldwide. The objective of study is to compare the correlation between hormones, lipid profile, oxidative stress and Zinc concentration in PCOS patients.

Methods: The present study examined hormone levels (progesterone, prolactin, luteinizing and follicle stimulation hormones (LH and FSH, respectively), antioxidant factors (catalase, glutathione-s- transferase), lipid profiles and zinc concentration of 50 Iraqi women patients' diagnosis with PCOS and 40 healthy women, divided in two age groups of 15-29 and 30-45 years. Body mass index was estimated for two age groups.

Results: The results showed decreasing of catalase, glutathione, and Zn concentrations with an increase in age. A slightly significant increase in LH and prolactin and decrease in high-density lipoprotein (HDL-C) with an increase in age in the patient group compared to the control group was noted.

Conclusion: Our study demonstrated that some factors (such as family history, genetics, environmental, etc…) could play a role in altering hormone levels, lipid profiles, and antioxidant. Controlling these factors may be useful for reducing the PCOS-associated problems in women's health. Needed extensive studies to assess the correlation with insulin resistant and obesity.

Citing Articles

Association of Serum Anti-Mullerian Hormone and Free Testosterone with Different Phenotypes of Polycystic Ovary Syndrome.

Gihad Falh Z, Oied Mohammed Saleh B, Mahjoob Al-Naddawi A Rep Biochem Mol Biol. 2024; 13(1):106-113.

PMID: 39582817 PMC: 11580133. DOI: 10.61186/rbmb.13.1.106.

Neuregulin 4 in Polycystic Ovarian Syndrome (PCOS) Phenotypes: A Key Role or Standby.

Abbood A, Majeed Hameed R, Ghazi Al Safi W Rep Biochem Mol Biol. 2024; 12(3):359-365.

PMID: 38618267 PMC: 11015924. DOI: 10.61186/rbmb.12.3.359.

A review of nitric oxide and oxidative stress in typical ovulatory women and in the pathogenesis of ovulatory dysfunction in PCOS.

Awonuga A, Camp O, Abu-Soud H Reprod Biol Endocrinol. 2023; 21(1):111.

PMID: 37996893 PMC: 10666387. DOI: 10.1186/s12958-023-01159-6.

Investigation of Zinc Supplement Impact on the Serum Biochemical Parameters in Pulmonary Tuberculosis: A Double Blinded Placebo Control Trial.

Zolfaghari B, Ghanbari M, Musavi H, Bavandpour Baghshahi P, Taghikhani M, Pourfallah F Rep Biochem Mol Biol. 2021; 10(2):173-182.

PMID: 34604407 PMC: 8480298. DOI: 10.52547/rbmb.10.2.173.

References

Jamilian M, Foroozanfard F, Bahmani F, Talaee R, Monavari M, Asemi Z . Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2015; 170(2):271-8. DOI: 10.1007/s12011-015-0480-7. View

Zhang J, Bao Y, Zhou X, Zheng L . Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019; 17(1):67. PMC: 6698037. DOI: 10.1186/s12958-019-0509-4. View

Nath C, Barman B, Das A, Rajkhowa P, Baruah P, Baruah M . Prolactin and thyroid stimulating hormone affecting the pattern of LH/FSH secretion in patients with polycystic ovary syndrome: A hospital-based study from North East India. J Family Med Prim Care. 2019; 8(1):256-260. PMC: 6396624. DOI: 10.4103/jfmpc.jfmpc_281_18. View

Zuo T, Zhu M, Xu W . Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxid Med Cell Longev. 2016; 2016:8589318. PMC: 4684888. DOI: 10.1155/2016/8589318. View

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Franks S, Gambineri A . The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014; 171(4):P1-29. DOI: 10.1530/EJE-14-0253. View

Sharquie K, Al-Bayatti A, Al-Ajeel A, Al-Bahar A, Al-Nuaimy A . Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J. 2007; 28(7):1039-43. View

Khalaf B . Leptin levels in relation to marital status and neuroendocrine function in Iraqi females with polycystic ovary syndrome. Saudi Pharm J. 2013; 18(1):41-4. PMC: 3730977. DOI: 10.1016/j.jsps.2009.12.005. View

Saeed N, Hamzah I, Al-Gharrawi S . Polycystic ovary syndrome dependency on mtDNA mutation; copy Number and its association with insulin resistance. BMC Res Notes. 2019; 12(1):455. PMC: 6657173. DOI: 10.1186/s13104-019-4453-3. View

Maluki A . The frequency of polycystic ovary syndrome in females with resistant acne vulgaris. J Cosmet Dermatol. 2010; 9(2):142-8. DOI: 10.1111/j.1473-2165.2010.00500.x. View

10.

Hillman S, Bryce C, Caleyachetty R, Dale J . Women's experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice. Br J Gen Pract. 2020; 70(694):e322-e329. PMC: 7065681. DOI: 10.3399/bjgp20X708881. View

11.

Spritzer P, Lecke S, Fabris V, Ziegelmann P, Amaral L . Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Biol Trace Elem Res. 2016; 175(2):254-262. DOI: 10.1007/s12011-016-0774-4. View

12.

Jamil A, Alalaf S, Al-Tawil N, Al-Shawaf T . Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2015; 293(2):447-56. DOI: 10.1007/s00404-015-3889-5. View

13.

Al-Obaidi M, Ali Z, Al-Saadi W, Al-Wasiti E, Al-Aubaidy H . Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome. J Clin Pharm Ther. 2019; 44(4):618-622. DOI: 10.1111/jcpt.12831. View

14.

Setji T, Brown A . Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014; 127(10):912-9. DOI: 10.1016/j.amjmed.2014.04.017. View

15.

Ndefo U, Eaton A, Green M . Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013; 38(6):336-55. PMC: 3737989. View

16.

Le M, Le V, Le D, Nguyen V, Chen C, Cao N . Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019; 90(4):579-585. DOI: 10.1111/cen.13934. View

17.

Abedini M, Ghaedi E, Hadi A, Mohammadi H, Amani R . Zinc status and polycystic ovarian syndrome: A systematic review and meta-analysis. J Trace Elem Med Biol. 2019; 52:216-221. DOI: 10.1016/j.jtemb.2019.01.002. View

18.

Barth J, Yasmin E, Balen A . The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf). 2007; 67(6):811-5. DOI: 10.1111/j.1365-2265.2007.02932.x. View